Amneal Pharmaceuticals, Inc.
AMRX
$6.98
$0.010.14%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 3.99% | 0.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.99% | 0.10% | |||
| Cost of Revenue | 7.75% | -3.97% | |||
| Gross Profit | -2.11% | 7.51% | |||
| SG&A Expenses | 8.42% | 1.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.00% | 1.53% | |||
| Operating Income | -10.04% | -8.91% | |||
| Income Before Tax | -199.33% | -24.42% | |||
| Income Tax Expenses | 47.93% | 1.33% | |||
| Earnings from Continuing Operations | -276.42% | -29.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 13.21% | -10.38% | |||
| Net Income | -19,823.72% | -102.60% | |||
| EBIT | -10.04% | -8.91% | |||
| EBITDA | -1.12% | -3.42% | |||
| EPS Basic | -19,960.00% | -102.58% | |||
| Normalized Basic EPS | -676.60% | -1,980.00% | |||
| EPS Diluted | -19,960.00% | -102.58% | |||
| Normalized Diluted EPS | -676.60% | -1,980.00% | |||
| Average Basic Shares Outstanding | 0.07% | 0.17% | |||
| Average Diluted Shares Outstanding | 0.07% | -2.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
